GlassScriptPhysician profile
Keisha Snow
NPI 1700214947
$2,721.75
in general payments reported to CMS, 2019-2025
25 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $669 · 2022: $604 · 2023: $625 · 2024: $556 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.52 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $341.66 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $339.04 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $287.66 | 2023-2025 | Myfembree, Gemtesa |
| Novo Nordisk INC | $287.47 | 2021-2024 | Wegovy |
| Abbvie INC. | $263.02 | 2021-2025 | |
| Pfizer INC. | $219.27 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.71 | 2021-2022 | |
| Lilly USA, LLC | $124.84 | 2021-2025 | Zepbound |
| Axsome Therapeutics, INC. | $106.39 | 2024 | Auvelity |
| Mayne Pharma Commercial LLC | $88.58 | 2023 | |
| Hologic Sales and Service, LLC | $74.78 | 2024-2025 | Aptima, Fluent Fluid Management System, Panther Fusion |
| Exeltis, USA INC. | $67.63 | 2024-2025 | Slynd |
| Regeneron Healthcare Solutions, INC. | $47.04 | 2023 | Dupixent |
| Channel Medsystems, INC. | $39.54 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.33 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.00 | 2021-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $25.22 | 2021 | |
| Biogen, INC. | $24.91 | 2024 | Zurzuvae |
| Agile Therapeutics, INC. | $22.89 | 2023 | Twirla |
| Medtronic, INC. | $21.43 | 2023 | Interstim |
| Organon LLC | $20.11 | 2024 | |
| Gynesonics, INC. | $17.44 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Axonics, INC. | $15.08 | 2023 | Bulkamid |
| Takeda Pharmaceuticals U.S.A., INC. | $14.37 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.